Syndax Pharmaceuticals Inc. (SNDX) Now Covered by Analysts at Guggenheim
Guggenheim assumed coverage on shares of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) in a research note issued to investors on Friday morning. The firm issued a buy rating and a $29.00 price objective on the stock.
Separately, Zacks Investment Research raised Syndax Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, June 16th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $25.80.
Syndax Pharmaceuticals (NASDAQ:SNDX) opened at 14.42 on Friday. The stock has a 50 day moving average price of $14.34 and a 200 day moving average price of $13.54. Syndax Pharmaceuticals has a 52-week low of $8.97 and a 52-week high of $18.03. The stock’s market cap is $256.42 million.
Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.07. On average, equities research analysts forecast that Syndax Pharmaceuticals will post ($3.01) EPS for the current year.
A number of institutional investors have recently modified their holdings of SNDX. BlackRock Inc. boosted its position in shares of Syndax Pharmaceuticals by 0.6% in the second quarter. BlackRock Inc. now owns 44,851 shares of the company’s stock valued at $442,000 after buying an additional 256 shares during the period. Kornitzer Capital Management Inc. KS boosted its position in shares of Syndax Pharmaceuticals by 13.8% in the second quarter. Kornitzer Capital Management Inc. KS now owns 45,500 shares of the company’s stock valued at $448,000 after buying an additional 5,500 shares during the period. Schwab Charles Investment Management Inc. bought a new position in shares of Syndax Pharmaceuticals during the second quarter valued at about $100,000. BlackRock Investment Management LLC boosted its position in shares of Syndax Pharmaceuticals by 99.4% in the second quarter. BlackRock Investment Management LLC now owns 36,068 shares of the company’s stock valued at $355,000 after buying an additional 17,982 shares during the period. Finally, Parametric Portfolio Associates LLC bought a new position in shares of Syndax Pharmaceuticals during the second quarter valued at about $229,000. Hedge funds and other institutional investors own 57.64% of the company’s stock.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.